| Unsubscribe |
I've spent two decades tracking the forces that move gold...
For 20 years I've lived inside the data, the cycles, the macro shifts...
And what's happening right now between Saudi Arabia and the Chinese is a turning point that will move the price of gold in a way we haven't seen in generations.
Because the Saudis have quietly walked away from a pact it struck with the U.S. in 1974...
A pact that quietly ran the global financial system for the past half-century.
The arrangement was simple: Saudi Arabia would price its oil only in U.S. dollars — which meant every nation on the planet had to stockpile U.S. Treasuries just to buy energy.
That single agreement is the bedrock American financial supremacy has rested on for fifty years.
And now, it's gone.
The mainstream press barely covered the unwinding of this deal...
And in the beginning, the surface looked calm.
But the cracks are now impossible to ignore...
Saudi Arabia inked a $7 billion currency swap with Beijing… Started clearing oil transactions in digital yuan… And plugged itself into mBridge, China's cross-border settlement network.
Conflict with Iran is pushing Gulf states toward yuan-denominated oil contracts...
And vessels moving through the Strait of Hormuz are now paying tolls in yuan, in crypto, in anything other than the greenback...
On both shores of the Persian Gulf, the dollar's grip is loosening... and something else is taking its place.
The collapse of this enormous, built-in global demand for dollars will rewrite how money works.
Because if crude no longer requires dollars, then the world has no reason to warehouse U.S. currency.
And when dollar demand softens… Treasury demand softens right alongside it.
Ten-year yields are already creeping toward 4.4% — the level where the machinery starts to seize up.
Weaker Treasury demand → climbing yields → Fed steps in → the printers fire up → and the dollars in your account quietly lose their muscle.
That's the chain reaction unfolding in front of us.
As the dollar weakens and foreign buyers walk away from American debt, gold has nowhere to go but up.
A sinking dollar is the most powerful tailwind gold has ever known.
But the smartest way to position for the dollar's decline isn't to load up on bullion…
There's a different vehicle for capturing gold's next leg higher...
An asset that's still priced at a dramatic discount to where gold itself is trading today.
It's gold exposure at a fraction of the cost...
Click here to see how it works.
Best,
Garrett Goggin, CFA, CMT
Chief Analyst and Founder, Golden Portfolio
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Written by Jessica Mitacek. Publication Date: 7/6/2026.
Key Points
- Employers are expected to drop coverage for GLP-1 weight-loss drugs in 2027, potentially driving patients toward Hims & Hers Health's telehealth subscription platform.
- Hims & Hers shares have surged more than 45% in 30 days and about 160% since their February low, leaving the stock technically overbought.
- Wall Street remains largely cautious on HIMS, with a consensus Hold rating, rising short interest, and increased insider selling despite the stock's rally.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
The healthcare sector has been one of the S&P 500’s best-performing groups over the past month, rising by about 6%. While that rebound has been led by a handful of mega-cap Big Pharma companies, it has also shown up in the performance of smaller names.
One of those is mid-cap Hims & Hers Health (NYSE: HIMS), the telehealth platform that provides direct-to-consumer (D2C) personal care products and virtual medical services.
3 AI stocks to buy before August 2026 (Ad)
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005.
Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.
Click here to get all three AI stock names from Alexander GreenOver the past 30 days, HIMS has gained more than 45%, bringing its year-to-date (YTD) advance to nearly 20%. After a move like that, the stock may be due for a short-term breather. But according to healthcare industry experts, a looming catalyst could deliver an outsized benefit to Hims & Hers in 2027 and beyond, setting up the stock as a buying opportunity on its next pullback.
The GLP-1 Craze Is Pushing Up Employers’ Healthcare Plan Costs
As the cost of weight-loss drugs continues to climb, Reuters recently reported that some employers are planning to drop coverage for GLP-1 treatments, including Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo—products manufactured by Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY).
Last year, more than 40% of employers covered weight-loss drugs, and estimates for this year are roughly the same. But analyses from two industry groups cited by Reuters suggest that is very likely to change in 2027.
According to the Business Group on Health, about 10% of employers that currently offer coverage for GLP-1 drugs for weight loss said they planned to drop them in 2027. A second survey from Mercer, a benefits consultancy, found that 5% of large employers plan to drop coverage in 2027 or are actively considering doing so.
While that is unfortunate news for those undergoing treatment, it is welcome news for HIMS shareholders. Patients losing healthcare coverage for GLP-1 drugs should benefit Hims & Hers Health, which currently generates around one-third of its revenue from its weight-loss business.
Analysts expect the company’s revenue to grow from an estimated $2.89 billion in 2026 to $3.45 billion in 2027, and increased subscription demand for weight-loss drugs amid shrinking insurance coverage should play a meaningful role in that top-line growth.
Lost coverage for GLP-1 treatments should also spur a migration to D2C telehealth providers, with Hims & Hers serving as a natural destination thanks to its platform, which bundles provider access, unlimited clinical consultations, and pharmacy fulfillment services into one streamlined subscription.
Technical Analysis and Wall Street Suggest a Correction Is Ahead
With its recurring revenue model, Hims & Hers should be a long-term beneficiary of reduced coverage. The platform charges a $39 fee for the first month of its weight-loss membership. After that, the charge rises to $149 for clinical subscriptions, not including the cost of the medication itself. Medication is billed separately, and Hims says the membership does not include or guarantee a prescription. Compounded oral options, for instance, can run from $145 to more than $199 per month, while branded GLP-1 pens like Wegovy can cost even more.
However, after gaining roughly 160% from its YTD low on Feb. 27, HIMS appears overdue for a price correction. According to the Relative Strength Index (RSI)—a technical momentum indicator that shows whether a stock is overbought (above 70), oversold (below 30), or fairly valued (somewhere in between)—HIMS has moved into overbought territory.
As shown by the green arrow below, the RSI on HIMS’ one-year chart currently reads 70.86, suggesting that the stock is overbought and due for a price reversal:
Technical analysis is hardly a perfect science. But the last two times the stock’s RSI breached 70—first in mid-April and then again in mid-June—HIMS pulled back more than 28% and nearly 8%, respectively, before continuing its rally.
Meanwhile, Wall Street remains bearish on the stock after its outperformance this year. Of the 16 analysts currently covering HIMS, only four rate it a Buy.
Overall, the stock carries a consensus Hold rating and a 12-month price target that implies more than 19% potential downside from current prices.
Concerningly, with a high-volatility beta of 2.35, current short interest in HIMS now stands at more than 32% of the float, or about 65.4 million shares valued at $1.97 billion.
That is the most the stock has been shorted since March and marks a nearly 5% month-over-month increase.
At the same time, insider activity has seen an uptick in selling this year. In Q1 2026, $3.46 million worth of HIMS shares were sold with no buys. In Q2, that figure rose to $4.86 million sold against $1.17 million bought.
Costco’s Cooling Comp Sales Keep Stock Stuck in Neutral for Now
Written by Dan Schmidt. Publication Date: 7/20/2026.
Key Points
- Costco's June comparable sales decelerated from May as fading gas price tailwinds and weakening international, especially Canadian, comps offset strong headline net sales growth.
- Costco trades at roughly 46 times forward earnings, more than double the retail sector average, making the stock vulnerable to any slowdown in comp sales growth.
- Costco shares have fallen about 15% from their all-time high and now show bearish technical signals, though long-term fundamentals like renewal rates remain strong.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
Costco Wholesale Club Inc. (NASDAQ: COST) recently reported its June sales numbers, and at first glance, it appears to be another strong month of growth for the country’s premier wholesale club.
However, the stock’s muted reaction shows how high the bar is for the company.
Most of your net worth in one stock? (Ad)
If a large share of your net worth is tied to a single stock, concentration risk may be working against your long-term plans - and selling without a strategy can stack a serious tax bill in one year.
SmartAsset's free quiz matches you with vetted fiduciary advisors who can build a sequenced, tax-aware plan around your specific position. A few minutes to match, then you choose who to talk to.
Take the free quiz and get matched with a fiduciary advisor todayWhen your multiple looks more like a tech-sector growth darling than a big-box retailer, “good” simply isn’t good enough.
And when you look beneath the surface, the latest sales numbers highlight an unnerving trend.
Strong Headline Numbers Obfuscate Underlying Weakness
Costco released its comp sales figures for June, and it’s a report that many other retailers would view with envy. Net sales for the period totaled $29.24 billion, up 10.6% year over year (YOY) and 7.6% when excluding gas and currency effects. The board also declared a $1.47-per-share dividend, payable in August with a record date of July 24. But despite these strong headline numbers, weakness is building under the surface.
Gas price volatility was a major tailwind for Costco as weary consumers turned to wholesale clubs for relief at the pump. Costco typically prices its gas below retail to drive volume and bring more people into its stores, also known as a loss leader. But now that gas prices are falling again, that tailwind is fading, and the June sales report tells the story. When stripping out gas and currency, the 7.6% U.S. comp number is a sharp deceleration from May’s 8.7% comps ex-gas and currency. The total decline is even steeper: 8.8% in June versus 12.5% in May, highlighting just how much fuel prices drove the advance.
U.S. stores may be in good shape, but the international market is becoming a growing concern. Canadian adjusted comps fell again, from 7.6% in April to 5.6% in May to 4.9% in June, and total international adjusted comps slipped from 8.0% in May to 7.0% in June. Soft international markets could limit upside if U.S. comp sales reaccelerate, now that fighting has resumed in Iran and gas prices are once again moving higher.
Stock Still Trades at Extreme Valuation Compared to Other Retailers
Costco remains an excellent business with a loyal membership base, strong overall sales growth (net sales were up 11.6% YOY as of May’s fiscal Q3 2026 report), and a hot dog-and-soda combo that still costs just $1.50. But the stock has long been priced for perfect execution, and when you trade at 46 times forward earnings with a Price/Earnings Growth (PEG) ratio of nearly 4.5, investors take notice of even the smallest crack in the armor.
The retail sector trades at about 21 times earnings, which is less than half Costco’s current valuation. While a company with Costco’s sales and membership profile deserves an elevated multiple, trading at more than twice the industry average while overall comp sales are declining is a blazing red flag that even a FIFA referee could see.
Prominent retailers like Walmart Inc. (NASDAQ: WMT) and Target Inc. (NYSE: TGT) trade at 40 and 18 times earnings, respectively, well below Costco’s valuation. Even a direct competitor like BJ’s Wholesale Club Holdings Inc. (NYSE: BJ) trades at 21 times earnings and 0.55 times sales.
Here’s one way to frame the new narrative shaping retail: the market is no longer looking for premium compounders like COST, which is up nearly 9% year to date, but cheap laggards like TGT, which is up more than 40% so far in 2026.
Technical Collapse Brings Shares Down With It
Costco’s fundamentals remain strong despite the sales slowdown, but the troubling technicals are showing up in full force. The stock briefly surged to a new all-time high in May following gasoline shocks tied to the Iran war, as new members flocked to stores after filling their tanks with cheap fuel. But once war hostilities faded, so did the rally in COST shares. The stock has pulled back approximately 15% from its previous all-time high, and the technical signals under the hood aren’t pointing to a rebound anytime soon.
Shares now trade below the 50-day and 200-day moving averages, and the Relative Strength Index (RSI) has been firmly in bearish territory since the end of May. The Moving Average Convergence Divergence (MACD) indicator also shows downward momentum continuing to build.
For long-term investors, this is likely not the time to sell, as the company still has 92% renewal rates and digitally enabled comps are a bright spot at 21%. But new investors are probably better off waiting for a more attractive entry point. A deceleration doesn’t mean deterioration, but a stock trading at 46 times earnings can’t afford even a brief slowdown if it wants to maintain bullish momentum.
This email content is a sponsored email sent on behalf of Golden Portfolio, a third-party advertiser of Earnings360 and MarketBeat.
If you have questions about your subscription, don't hesitate to contact MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Place #620, Sioux Falls, S.D. 57103-7078. USA..
Post a Comment
0Comments